New ADHD pill for kids shows promise in Late-Stage trial

NCT ID NCT06359899

Completed Disease control Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral capsule called AK0901 (AZSTARYS) in children aged 6 to 12 with attention deficit hyperactivity disorder (ADHD). The trial compares the drug against a placebo to see if it reduces ADHD symptoms like inattention and hyperactivity. Researchers measure symptom changes using a standard rating scale over several weeks. The goal is to determine if AK0901 is a safe and effective treatment option for this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK0901 (AZSTARYS, a combination of serdexmethylphenidate and dexmethylphenidate)
What this could lead to: If successful, this could provide a new oral medication option to help manage ADHD symptoms in children aged 6-12.
What could go wrong: This is a relatively small Phase 3 trial, and results may not confirm effectiveness or safety for all children. Common ADHD medication risks include appetite loss, sleep problems, and mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD

Contacts and locations

Locations

Beijing anding hospital capital medical university

Beijing, Beijing Municipality, China
Peking university sixth hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.